Novartis Reports Phase 2 Data for Trastuzumab deruxtecan in Asthma

Novartis today announced Phase 2 results for trastuzumab deruxtecan in patients with asthma. The study demonstrated that trastuzumab deruxtecan reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of asthma and support the continued development of trastuzumab deruxtecan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.